Welcome to our dedicated page for Oncocyte Corporation news (Ticker: OCX), a resource for investors and traders seeking the latest updates and insights on Oncocyte Corporation stock.
Oncocyte Corp. (Nasdaq: OCX) is a diagnostics technology company focused on molecular tests for organ transplantation and oncology, and its news flow reflects this dual focus. Company updates frequently describe progress toward commercializing a dd-cfDNA-based transplant rejection monitoring test kit, including clinical trial milestones, regulatory interactions, and reimbursement developments. Oncocyte also reports on the use of its proprietary assays in peer-reviewed studies and collaborations with leading transplant centers and research institutions.
Investors and clinicians following OCX news can expect regular announcements about the GraftAssure transplant portfolio, which includes the GraftAssureCore lab-developed test, the GraftAssureIQ research-use-only kit, and the planned GraftAssureDx in-vitro diagnostic kit. Recent releases have highlighted Medicare reimbursement improvements for the company’s lab-developed transplant assay, expanded coverage for specific high-risk patient groups, and adoption of GraftAssure research kits by transplant centers in the United States, Europe, and Southeast Asia.
Oncocyte’s news also covers scientific publications that use its proprietary assays to study transplant biology, such as data in Transplantation Direct examining dd-cfDNA levels and kidney allograft biopsies. In oncology, updates have discussed the role of the DetermaIO gene expression test in studies like NeoTRIP in triple negative breast cancer, as well as the DetermaCNI blood-based monitoring tool.
In addition, OCX news items report on quarterly and annual financial results, pharma services revenue from its CLIA-certified Nashville lab, capital raises, and its strategic partnership with Bio-Rad Laboratories. Corporate communications may also include participation in healthcare and diagnostics conferences and plans related to corporate renaming. For those tracking the company, the news stream provides insight into clinical, regulatory, scientific, and capital markets developments affecting Oncocyte’s transplant and oncology diagnostics programs.
Oncocyte Corporation (NYSE American: OCX) announced presentations at the 2020 ASCO, focusing on the DetermaIO™ test and its application in triple-negative breast cancer (TNBC). The results suggest that DetermaIO could identify patients likely to respond to checkpoint inhibitor therapy. Additionally, the DetermaRx™ test presents potential healthcare savings of up to $450 million through improved disease-free survival for lung cancer patients. The company aims to make DetermaRx more accessible following recent Medicare coverage changes.
Oncocyte Corporation (OCX) announced significant advancements in its molecular diagnostics, particularly with DetermaRx™, which may be covered by Medicare for 70% of eligible early-stage NSCLC patients. The company secured international collaboration with CORE Diagnostics for DetermaRx™ distribution in India and the Middle East. Financial results showed a net loss of $7.7 million for Q1 2020, up from $3.9 million in the previous year, largely due to increased operational costs. Cash reserves were at $16.9 million as of March 31, 2020. The company continues to expand its pharma services and aims for broader reimbursement options.
Summary not available.
Summary not available.